◆英語タイトル:ChemoCentryx Inc (CCXI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7994
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
ChemoCentryx Inc (ChemoCentryx) is a biopharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases, and inflammatory disorders. The company’s lead drug candidate include Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; CCX872, an orally administered inhibitor for pancreatic cancer; and CCX140, an orally-administered inhibitor of the chemokine receptor known for patients with diabetic nephropathy, among others. It also carries out preclinical research for evaluating the effect of combination therapy with chemokine receptor and check point inhibitors. ChemoCentryx is headquartered in Mountain View, California, the US.
ChemoCentryx Inc (CCXI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ChemoCentryx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ChemoCentryx to Raise USD50 Million in Financing 10
Licensing Agreements 11
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 11
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 12
Equity Offering 13
ChemoCentryx Withdraws Public Offering of Shares for USD75 Million 13
ChemoCentryx Completes Public Offering Of Common Stock For US$69 Million 15
ChemoCentryx Raises USD7 million in Private Placement of Shares 16
ChemoCentryx Completes IPO Of Common Stock For US$45 Million 17
ChemoCentryx Completes Private Placement Of Shares For US$5 Million 19
Acquisition 20
Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 20
ChemoCentryx Inc – Key Competitors 22
ChemoCentryx Inc – Key Employees 23
ChemoCentryx Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 09, 2018: Chemocentryx reports second quarter 2018 financial results and recent highlights 25
May 09, 2018: ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights 27
Mar 09, 2018: ChemoCentryx Reports Fourth Quarter And Full Year 2017 Financial Results And Recent Highlights 28
Nov 07, 2017: ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights 30
Aug 08, 2017: ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights 31
May 10, 2017: ChemoCentryx Reports First Quarter 2017 Financial Results 32
Mar 14, 2017: ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results 33
Corporate Communications 34
Jan 08, 2018: ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Tables
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ChemoCentryx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ChemoCentryx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ChemoCentryx to Raise USD50 Million in Financing 10
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 11
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 12
ChemoCentryx Withdraws Public Offering of Shares for USD75 Million 13
ChemoCentryx Completes Public Offering Of Common Stock For US$69 Million 15
ChemoCentryx Raises USD7 million in Private Placement of Shares 16
ChemoCentryx Completes IPO Of Common Stock For US$45 Million 17
ChemoCentryx Completes Private Placement Of Shares For US$5 Million 19
Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 20
ChemoCentryx Inc, Key Competitors 22
ChemoCentryx Inc, Key Employees 23
ChemoCentryx Inc, Subsidiaries 24
List of Figures
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8